Company news

INmune Bio Inc. news in 2019

INmune Bio Inc.'s news releases, calls and decks from 2019, newest first.

View company

INmune Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03, Demonstrates Efficacy and Safety; INB03 is Advancing to Phase II Trials

December 16, 2019

INmune Bio, Inc. Announces First Alzheimer’s Disease Patient Dosed in XPro1595 Study

December 1, 2019

INmune Bio, Inc. Strengthens Board of Directors with Appointment of Veteran Finance Executive Marcia Allen

November 18, 2019

INmune Bio, Inc. Reports Third Quarter 2019 Financial Results and Provides Shareholder Update

November 7, 2019

INmune Bio, Inc. Announces Potentially Strong Link Between Obesity and Alzheimer's Disease at the Society for Neuroscience 49th Annual Meeting

October 20, 2019

INmune Bio, Inc. Announces Presentation of Data Related to its Lead Compound XPro1595 at the Society for Neuroscience’s Annual Meeting

October 16, 2019

INmune Bio Inc. Announces USPTO Allowance of Key Patent Covering Its DN-TNFa Platform Technology for Treating Cancer

September 11, 2019

Decks in 2019